Clinical trial
Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian…
NCT00086632 · Unither Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00086632 |
|---|---|
| Title | Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment |
| Official title | An Open-Label, Phase II Study of Ovarex® MAb-B43.13 as an Adjuvant Treatment to Platinum-Based Front-Line Chemotherapy of Advanced Epithelial Carcinoma of Ovarian, Tubal, or Peritoneal Origin |
| Lead sponsor | Unither Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | oregovomab |
| Enrollment | 40 |
| Start date | Jul 1, 2004 |
| Completion | Dec 1, 2007 |
| First posted | Jul 9, 2004 |
| Last update posted | Dec 18, 2007 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: